ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
The overexpressed ErbB2/HER2 receptor is a clinically validated cancer target whose surface localization and internalization mechanisms remain poorly understood. Downregulation of the overexpressed 185-kDa ErbB2 receptor is rapidly (2-6 hours) induced by the HSP90 chaperone inhibitor geldanamycin (GA), whereas its downregulation and lysosomal degradation are more slowly (24 hours) induced by the proteasome inhibitor bortezomib/PS341. In PS341-treated SK-BR-3 cells, overexpressed ErbB2 coprecipitates with the E3 ubiquitin ligase c-Cbl and also with the deubiquitinating enzyme USP9x; moreover, siRNA downregulation of USP9x enhances PS341-induced ErbB2 downregulation. Because polyubiquitin linkages via lysine 48 (K48) or 63 (K63) can differentially address proteins for 26S proteasomal degradation or endosome trafficking to the lysosome, multiple reaction monitoring (MRM)/mass spectrometry (MS) and polyubiquitin linkage-specific antibodies were used to quantitatively track K48-linked and K63-linked ErbB2 polyubiquitination following either GA or PS341 treatment of SK-BR-3 cells. MRM/MS revealed that unlike the rapid, modest (4-fold to 8-fold), and synchronous GA induction of K48 and K63 polyubiquitinated ErbB2, PS341 produces a dramatic (20-fold to 40-fold) sequential increase in polyubiquitinated ErbB2 consistent with K48 polyubiquitination followed by K63 editing. Fluorescence microscopic imaging confirmed that PS341, but not GA, induces colocalization of K48-linked and K63-linked polyubiquitin with perinuclear lysosome-sequestered ErbB2. Thus, ErbB2 surface overexpression and recycling seem to depend on its polyubiquitination and deubiquitination; as well, the contrasting effects of PS341 and GA on ErbB2 receptor localization, polyubiquitination, and degradation point to alternate cytoplasmic trafficking likely regulated by different K48 and K63 polyubiquitin editing mechanisms.
Marx
Corina
C
Buck Institute for Age Research, Novato, California 94945, USA.
Held
Jason M
JM
Gibson
Bradford W
BW
Benz
Christopher C
CC
D016227:Benzoquinones / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D001943:Breast Neoplasms / Q000201:enzymology; D045744:Cell Line, Tumor; D002966:Clathrin / Q000378:metabolism; D015536:Down-Regulation; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology; D008247:Lysosomes / Q000201:enzymology / Q000378:metabolism; D013058:Mass Spectrometry / Q000379:methods; D008856:Microscopy, Fluorescence; D011480:Protease Inhibitors / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000378:metabolism*; D054875:Ubiquitination
D016227:Benzoquinones; D001897:Boronic Acids; D000069286:Bortezomib; D002966:Clathrin; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D011480:Protease Inhibitors; D046988:Proteasome Endopeptidase Complex; D061988:Proteasome Inhibitors; D011719:Pyrazines; D018719:Erb-b2 Receptor Tyrosine Kinases; C001277:geldanamycin
BMC Struct Biol. 2008 May 16;8:26
18485199
J Cell Biol. 2009 May 4;185(3):493-502
19398763
Mol Biol Cell. 2007 Oct;18(10):3952-65
17686993
Cancer Res. 2000 Jul 1;60(13):3384-8
10910043
Nat Cell Biol. 2005 Aug;7(8):750-7
16056266
Mol Biol Cell. 2004 Apr;15(4):1557-67
14742716
J Biol Chem. 2000 Aug 25;275(34):26625-31
10862618
Cancer Res. 2008 Jul 15;68(14):5669-77
18632619
Cell Div. 2007 Mar 13;2:11
17355622
Exp Cell Res. 2008 Oct 15;314(17):3093-106
18793634
Histochem Cell Biol. 2008 May;129(5):563-78
18288481
Clin Breast Cancer. 2008 Oct;8(5):392-401
18952552
Mol Biol Cell. 2004 Apr;15(4):1591-9
14742711
Mol Cancer Res. 2008 Mar;6(3):491-500
18337455
Am J Physiol Endocrinol Metab. 2009 May;296(5):E973-84
19240253
J Cell Biol. 2006 May 22;173(4):463-8
16702236
Cancer Biol Ther. 2008 Oct;7(10):1630-40
18769124
Mol Cell Biol. 2008 Aug;28(15):4805-18
18519587
Mol Cell Biol. 2007 Jul;27(13):5029-39
17452457
Cell Cycle. 2004 Jan;3(1):51-60
14657666
J Neurosci. 2005 Feb 23;25(8):2002-9
15728840
Nature. 1997 Feb 20;385(6618):737-40
9034192
Mol Cell. 2006 Mar 17;21(6):737-48
16543144
J Cell Sci. 2008 Oct 1;121(Pt 19):3155-66
18765569
Mol Biol Cell. 2007 Sep;18(9):3656-66
17626164
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12847-52
12239347
Cell. 2008 Aug 22;134(4):668-78
18724939
Nat Rev Cancer. 2009 Jul;9(7):463-75
19536107
Mol Biol Cell. 2009 Apr;20(7):2015-29
19176755
Nat Cell Biol. 2006 Jul;8(7):700-10
16799550
J Biol Chem. 1996 Sep 13;271(37):22796-801
8798456
Cancer Res. 2008 Nov 15;68(22):9280-90
19010901
Mol Pharmacol. 2007 Jun;71(6):1525-34
17392524
Cancer Res. 2006 Jul 1;66(13):6732-40
16818648
J Biol Chem. 2003 Apr 18;278(16):13829-37
12574167
Mol Biol Cell. 2004 Dec;15(12):5268-82
15385631